MX2020008188A - Conjugados de fármacos de molécula pequeña de monofosfato de gemcitabina. - Google Patents

Conjugados de fármacos de molécula pequeña de monofosfato de gemcitabina.

Info

Publication number
MX2020008188A
MX2020008188A MX2020008188A MX2020008188A MX2020008188A MX 2020008188 A MX2020008188 A MX 2020008188A MX 2020008188 A MX2020008188 A MX 2020008188A MX 2020008188 A MX2020008188 A MX 2020008188A MX 2020008188 A MX2020008188 A MX 2020008188A
Authority
MX
Mexico
Prior art keywords
sup
small molecule
drug conjugates
molecule drug
gemcitabine monophosphate
Prior art date
Application number
MX2020008188A
Other languages
English (en)
Inventor
Craig Alan Coburn
Steven Albert Everett
Original Assignee
Maverix Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maverix Oncology Inc filed Critical Maverix Oncology Inc
Publication of MX2020008188A publication Critical patent/MX2020008188A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/24—Post-translational modifications [PTMs] in chemical analysis of biological material hydroxylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se revelan compuestos que tienen la fórmula (I): (ver formula) o una de sus sales, ésteres, amidas, solvatos o estereoisómeros farmacéuticamente aceptables, en donde L, Y1, Y2, Y3, Y4, Y5, Z1, Z2, Z3, Z4, Z5, Z6 son cada uno como se definen en la memoria descriptiva; sus composiciones; sus usos; y sus métodos de uso.
MX2020008188A 2018-02-02 2019-02-04 Conjugados de fármacos de molécula pequeña de monofosfato de gemcitabina. MX2020008188A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862625820P 2018-02-02 2018-02-02
PCT/US2019/016557 WO2019152955A1 (en) 2018-02-02 2019-02-04 Small molecule drug conjugates of gemcitabine monophosphate

Publications (1)

Publication Number Publication Date
MX2020008188A true MX2020008188A (es) 2020-11-18

Family

ID=65494554

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008188A MX2020008188A (es) 2018-02-02 2019-02-04 Conjugados de fármacos de molécula pequeña de monofosfato de gemcitabina.

Country Status (17)

Country Link
US (1) US11760773B2 (es)
EP (1) EP3746134A1 (es)
JP (2) JP2021512953A (es)
KR (1) KR20200118827A (es)
CN (1) CN112135634A (es)
AU (1) AU2019216531A1 (es)
BR (1) BR112020015745A2 (es)
CA (1) CA3091027A1 (es)
CL (1) CL2020002022A1 (es)
CO (1) CO2020010970A2 (es)
EA (1) EA202091856A1 (es)
IL (1) IL276436A (es)
MX (1) MX2020008188A (es)
PE (1) PE20210367A1 (es)
PH (1) PH12020551182A1 (es)
SG (1) SG11202007386RA (es)
WO (1) WO2019152955A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512953A (ja) * 2018-02-02 2021-05-20 メイベリックス オンコロジー インコーポレイテッド ゲムシタビンモノホスフェートの小分子薬物コンジュゲート

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU389090A1 (ru) 1971-05-17 1973-07-05 Ташкентский государственный медицинский институт Библиотека
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US5229272A (en) 1989-04-25 1993-07-20 Igen, Inc. Catalytic antibody components
ZA859008B (en) 1984-12-04 1987-07-29 Lilly Co Eli The treatment of tumors in mammals
CA1264738A (en) 1984-12-04 1990-01-23 Eli Lilly And Company Treatment of tumors in mammals
ES2058073T3 (es) 1986-04-30 1994-11-01 Otsuka Pharma Co Ltd Derivados de 5-fluorouracilo.
US6702705B1 (en) 1988-05-04 2004-03-09 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
WO1989011484A1 (en) 1988-05-25 1989-11-30 Research Corporation Technologies, Inc. Phosphoramides useful as antitumor agents
DE3834860A1 (de) 1988-10-13 1990-04-19 Basf Ag Heterocyclisch substituierte alkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel
DE3834861A1 (de) 1988-10-13 1990-04-19 Basf Ag Arylalkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel
US6258360B1 (en) 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US6060592A (en) 1990-01-11 2000-05-09 Isis Pharmaceuticals, Inc. Pyrimidine nucleoside compounds and oligonucleoside compounds containing same
US5401838A (en) 1992-06-22 1995-03-28 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
ATE250060T1 (de) 1993-06-08 2003-10-15 Cancer Rec Tech Ltd O6-substituierte guaninederivate, verfahren zu ihre herstellung und ihre anwendung für behandlung von tumorzellen
ES2257756T3 (es) 1996-03-12 2006-08-01 Sanofi-Aventis Deutschland Gmbh Nuevos profarmacos para la terapia de tumores y enfermedades inflamatorias.
WO1998011484A1 (fr) 1996-09-13 1998-03-19 Hitachi, Ltd. Processeur de commande a memoire d'historique
WO1998032762A1 (en) 1997-01-24 1998-07-30 Norsk Hydro Asa Gemcitabine derivatives
NZ330360A (en) 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
TW434252B (en) 1997-07-23 2001-05-16 Univ Georgia Res Found Process for the preparation of 2'-fluoro-5-methyl-β-L-arabino-furanosyluridine
AU2173899A (en) 1998-02-06 1999-08-23 De Montfort University Hydroxylation activated prodrugs
DE69909073T2 (de) 1998-02-12 2004-05-19 De Montfort University Durch hydroxylierung aktivierte wirkstofffreigabe
DE19834751A1 (de) 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
NZ521028A (en) 2000-03-16 2004-07-30 F Carboxylic acid derivatives as IP antagonists
GB0007401D0 (en) 2000-03-27 2000-05-17 Cancer Res Campaign Tech Substituted chalcones as therapeeutic compounds
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
JP3692927B2 (ja) 2000-11-07 2005-09-07 日本電気株式会社 ファクシミリ装置
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
KR100559015B1 (ko) 2001-03-02 2006-03-10 에프. 호프만-라 로슈 아게 Ｉｐ 길항제로서의 알콕시카보닐아미노 벤조산 또는알콕시카보닐아미노 테트라졸릴 페닐 유도체
ES2293448T3 (es) 2001-05-18 2008-03-16 Hess Engineering, Inc. Metodo y aparato para fabricar un convertidor catalitico.
MXPA04001785A (es) 2001-09-14 2004-07-08 Bayer Ag Benzofurano y derivados de dihidrobenzofurano utiles como agonistas de beta-3 adrenoreceptores.
EP1300403A1 (en) 2001-10-02 2003-04-09 Aventis Pharma S.A. Process for the manufacture of hypoxyxylerone derivatives
GB0123777D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
GB0123780D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
WO2004041203A2 (en) 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
KR20110079783A (ko) 2003-02-19 2011-07-07 예일 유니버시티 항-바이러스 뉴클레오시드 유사체 및 바이러스 감염, 특히 에이치아이브이 감염의 치료방법
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
JP2007525406A (ja) 2003-12-04 2007-09-06 ワイス ビアリールスルホンアミドおよびその使用方法
DE602004015331D1 (de) 2003-12-22 2008-09-04 Hoffmann La Roche Verfahren für fluorcytidinderivate
EP3075247B1 (en) 2004-02-02 2022-10-12 BioSight Ltd. Conjugates for cancer therapy and diagnosis
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
GB0421294D0 (en) 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
RS50629B (sr) 2004-12-17 2010-06-30 Eli Lilly And Company Amidni prolek gemcitabina, kompozicije i njihova primena
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
NO322682B1 (no) 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
EP1937658A1 (en) 2005-10-06 2008-07-02 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
EP1994042A4 (en) 2006-02-06 2009-03-18 Reddys Lab Ltd Dr PREPARATION OF GEMCITABINE
US20080182816A1 (en) 2006-02-23 2008-07-31 Tam Joemy C Methods for preparing a novel family of polysaccharride prodrugs for colonic delivery
US20070225248A1 (en) 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
CA2681222C (en) 2007-03-19 2016-07-26 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The University Of Oregon Mannich base n-oxide drugs
CN100475832C (zh) 2007-05-31 2009-04-08 南京卡文迪许生物工程技术有限公司 一种新颖的高立体选择性合成吉西他滨工艺及中间体
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
TWI415858B (zh) 2007-11-06 2013-11-21 Pharmaessentia Corp β－核苷之新穎合成技術
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US9937128B2 (en) * 2009-08-03 2018-04-10 The University Of North Carolina At Chapel Hill Liposomes comprising a calcium phosphate-containing precipitate
US20130131008A1 (en) * 2011-10-25 2013-05-23 Board Of Regents, The University Of Texas System Lipophilic monophosphorylated derivatives and nanoparticles
WO2014074725A1 (en) 2012-11-07 2014-05-15 Ohio State Innovation Foundation Substituted gemcitabine aryl amide analogs
WO2014145207A1 (en) * 2013-03-15 2014-09-18 Ohio State Innovation Foundation Substituted gemcitabine bicyclic amide analogs and treatment methods using same
US10059733B2 (en) 2014-03-03 2018-08-28 Nucorion Pharmaceuticals, Inc. Gemcitabine analogs
CN105001291B (zh) * 2014-04-15 2018-12-04 上海知萌生物医药科技有限公司 吉西他滨化学传递前药及其制备方法和应用
CN105001191A (zh) * 2015-07-23 2015-10-28 广西师范学院 具有5,2’-二羟基-4’-甲氧基-3-香叶基黄酮骨架的衍生物及其制备方法和用途
EP3746133A1 (en) * 2018-02-02 2020-12-09 Maverix Oncology, Inc. Novel small molecule drug conjugates of gemcitabine derivatives
JP2021512953A (ja) * 2018-02-02 2021-05-20 メイベリックス オンコロジー インコーポレイテッド ゲムシタビンモノホスフェートの小分子薬物コンジュゲート

Also Published As

Publication number Publication date
PE20210367A1 (es) 2021-02-26
EA202091856A1 (ru) 2020-12-07
US11760773B2 (en) 2023-09-19
CO2020010970A2 (es) 2020-11-20
KR20200118827A (ko) 2020-10-16
WO2019152955A1 (en) 2019-08-08
WO2019152955A9 (en) 2020-08-13
IL276436A (en) 2020-09-30
JP2021512953A (ja) 2021-05-20
CL2020002022A1 (es) 2021-02-12
EP3746134A1 (en) 2020-12-09
JP2024054873A (ja) 2024-04-17
US20210040136A1 (en) 2021-02-11
AU2019216531A1 (en) 2020-09-24
PH12020551182A1 (en) 2021-05-10
SG11202007386RA (en) 2020-08-28
CN112135634A (zh) 2020-12-25
BR112020015745A2 (pt) 2020-12-08
CA3091027A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
MX2020005363A (es) Compuestos heterociclicos como inhibidores de prmt5.
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
EP4365179A3 (en) Novel rapamycin derivatives
EP2613782A4 (en) INDAZOLE DERIVATIVES AS INHIBITORS OF THE ERK PATHWAY
IN2012DN03085A (es)
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
TW200613243A (en) Novel compounds
MY151986A (en) Adamantyl diamide derivatives and uses of same
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
UY30310A1 (es) Derivados 2-azetidinona, sales, solvatos, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
MX2023012743A (es) Derivado de fosfonilo, y composición y aplicación farmacéutica de éste.
MX2021014680A (es) Derivado de benzotriazol.
SE0402925D0 (sv) Novel Compounds
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
CY1108584T1 (el) Παραγωγα 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline ως φαρμακα για τη θεραπεια της στειροτητας
MX2012004835A (es) Derivados de espirolactama y usos de los mismos.
PH12020551178A1 (en) Novel small molecule drug conjugates of gemcitabine derivatives
ZA202203107B (en) Azaindole carboxamide compounds for the treatment of mycobacterial infections
MX2020013729A (es) Compuestos de cianotriazol y usos de los mismos.